Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma

被引：3

作者：

Fakhri, Bita ^{[1
]}

Yilmaz, Elif ^{[2
]}

Gao, Feng ^{[3
]}

Ambinder, Richard F. ^{[4
]}

Jones, Richard ^{[4
]}

Bartlett, Nancy L. ^{[1
]}

Cashen, Amanda ^{[1
]}

Wagner-Johnston, Nina ^{[4
]}

机构：

[1] Washington Univ, Dept Med, Div Med Oncol, Sch Med, St Louis, MO 63130 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Div Hematol & Oncol, Dept Med, Washington, DC 20052 USA

[3] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO 63110 USA

[4] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 10期

关键词：

Autologous hematopoietic cell transplantation; allogeneic hematopoietic cell transplantation; relapsed Hodgkin lymphoma; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; BRENTUXIMAB VEDOTIN; SALVAGE THERAPY; SINGLE-ARM; NIVOLUMAB; PEMBROLIZUMAB; CHEMOTHERAPY; DISEASE; CYCLOPHOSPHAMIDE;

D O I：

10.1080/10428194.2021.1927016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For relapsed Hodgkin lymphoma, salvage chemotherapy followed by auto-HCT is the standard of care. It is important to identify subpopulations who could benefit from allo-HCT. This retrospective analysis included 277 patients with rrHL who underwent first transplant with auto-HCT or allo-HCT between 2007-2017. Patients in the auto-HCT cohort (N = 218) were older, more likely to be in CR at the time of transplant and receive maintenance therapy post-transplant. Patients who underwent allo-HCT (N = 59) had a higher MSKCC relapse score. Factors associated with an inferior PFS and OS included early relapse, advanced stage, extranodal involvement and not achieving CR following salvage chemotherapy. After controlling for these 4 risk factors and MSKCC score, PFS (p = 0.112) or OS (p = 0.256) was not affected by the choice of transplant. In patients with >= 3 high risk features, the 4-year PFS was 51% in the allo-HCT vs. 39% (p = 0.107) in the auto-HCT cohort.

引用

页码：2408 / 2415

页数：8

共 40 条

[21] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma [J].

LaCasce, Ann S. ;

Bociek, R. Gregory ;

Sawas, Ahmed ;

Caimi, Paolo ;

Agura, Edward ;

Matous, Jeffrey ;

Ansell, Stephen M. ;

Crosswell, Howland E. ;

Islas-Ohlmayer, Miguel ;

Behler, Caroline ;

Cheung, Eric ;

Forero-Torres, Andres ;

Vose, Julie ;

O'Connor, Owen A. ;

Josephson, Neil ;

Wang, Yinghui ;

Advani, Ranjana .

BLOOD, 2018, 132 (01) :40-48

[22] DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].

LINCH, DC ;

WINFIELD, D ;

GOLDSTONE, AH ;

MOIR, D ;

HANCOCK, B ;

MCMILLAN, A ;

CHOPRA, R ;

MILLIGAN, D ;

HUDSON, GV .

LANCET, 1993, 341 (8852) :1051-1054

[23] HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J].

Luznik, Leo ;

O'Donnell, Paul V. ;

Symons, Heather J. ;

Chen, Allen R. ;

Leffell, M. Susan ;

Zahurak, Marianna ;

Gooley, Ted A. ;

Piantadosi, Steve ;

Kaup, Michele ;

Ambinder, Richard F. ;

Huff, Carol Ann ;

Matsui, William ;

Bolanos-Meade, Javier ;

Borrello, Ivan ;

Powell, Jonathan D. ;

Harrington, Elizabeth ;

Warnock, Sandy ;

Flowers, May ;

Brodsky, Robert A. ;

Sandmaier, Brenda M. ;

Storb, Rainer F. ;

Jones, Richard J. ;

Fuchs, Ephraim J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) :641-650

[24] Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma [J].

Majhail, Navneet S. ;

Weisdorf, Daniel J. ;

Defor, Todd E. ;

Miller, Jeffrey S. ;

McGlave, Philip R. ;

Slungaard, Arne ;

Arora, Mukta ;

Ramsay, Norma K. C. ;

Orchard, Paul J. ;

MacMillan, Margaret L. ;

Burns, Linda J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) :1065-1072

[25] Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi [J].

Merli, Francesco ;

Luminari, Stefano ;

Gobbi, Paolo G. ;

Cascavilla, Nicola ;

Mammi, Caterina ;

Ilariucci, Fiorella ;

Stelitano, Caterina ;

Musso, Maurizio ;

Baldini, Luca ;

Galimberti, Sara ;

Angrilli, Francesco ;

Polimeno, Giuseppe ;

Scalzulli, Potito Rosario ;

Ferrari, Angela ;

Marcheselli, Luigi ;

Federico, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) :1175-+

[26] Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma [J].

Merryman, Reid W. ;

Redd, Robert A. ;

Nishihori, Taiga ;

Chavez, Julio ;

Nieto, Yago ;

Darrah, Justin M. ;

Rao, Uttam ;

Byrne, Michael T. ;

Bond, David A. ;

Maddocks, Kami J. ;

Spinner, Michael A. ;

Advani, Ranjana H. ;

Ballard, Hatcher J. ;

Svoboda, Jakub ;

Singh, Anurag K. ;

McGuirk, Joseph P. ;

Modi, Dipenkumar ;

Ramchandren, Radhakrishnan ;

Romancik, Jason ;

Cohen, Jonathon B. ;

Frigault, Matthew J. ;

Chen, Yi-Bin ;

Serritella, Anthony, V ;

Kline, Justine ;

Ansell, Stephen ;

Nathan, Sunita ;

Rahimian, Maryam ;

Joyce, Robin M. ;

Shah, Mansi ;

David, Kevin A. ;

Park, Steven ;

Beaven, Anne W. ;

Habib, Alma ;

Bachanova, Veronika ;

Nakhoda, Shazia ;

Khan, Nadia ;

Lynch, Ryan C. ;

Smith, Stephen D. ;

Ho, Vincent T. ;

LaCasce, Ann ;

Armand, Philippe ;

Herrera, Alex F. .

BLOOD ADVANCES, 2021, 5 (06) :1648-1659

[27] PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study [J].

Moskowitz, Alison J. ;

Schoeder, Heiko ;

Yahalom, Joachim ;

McCall, Susan J. ;

Fox, Stephanie Y. ;

Gerecitano, John ;

Grewal, Ravinder ;

Hamlin, Paul A. ;

Horwitz, Steven ;

Kobos, Rachel ;

Kumar, Anita ;

Matasar, Matthew ;

Noy, Ariela ;

Palomba, M. Lia ;

Perales, Miguel-Angel ;

Portlock, Carol S. ;

Sauter, Craig ;

Shukla, Neerav ;

Steinherz, Peter ;

Straus, David ;

Trippett, Tanya ;

Younes, Anas ;

Zelenetz, Andrew ;

Moskowitz, Craig H. .

LANCET ONCOLOGY, 2015, 16 (03) :284-292

[28] A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model [J].

Moskowitz, CH ;

Nimer, SD ;

Zelenetz, AD ;

Trippett, T ;

Hedrick, EE ;

Filippa, D ;

Louie, D ;

Gonzales, M ;

Walits, J ;

Coady-Lyons, N ;

Qin, J ;

Frank, R ;

Bertino, JR ;

Coy, A ;

Noy, A ;

O'Brien, JP ;

Straus, D ;

Portlock, CS ;

Yahalom, J .

BLOOD, 2001, 97 (03) :616-623

[29] Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse [J].

Moskowitz, Craig H. ;

Walewski, Jan ;

Nademanee, Auayporn ;

Masszi, Tamas ;

Agura, Edward ;

Holowiecki, Jerzy ;

Abidi, Muneer H. ;

Chen, Andy I. ;

Stiff, Patrick ;

Viviani, Simonetta ;

Bachanova, Veronika ;

Sureda, Anna ;

McClendon, Teresa ;

Lee, Connie ;

Lisano, Julie ;

Sweetenham, John .

BLOOD, 2018, 132 (25) :2639-2642

[30] Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Moskowitz, Craig H. ;

Nademanee, Auayporn ;

Masszi, Tamas ;

Agura, Edward ;

Holowiecki, Jerzy ;

Abidi, Muneer H. ;

Chen, Andy I. ;

Stiff, Patrick ;

Gianni, Alessandro M. ;

Carella, Angelo ;

Osmanov, Dzhelil ;

Bachanova, Veronika ;

Sweetenham, John ;

Sureda, Anna ;

Huebner, Dirk ;

Sievers, Eric L. ;

Chi, Andy ;

Larsen, Emily K. ;

Hunder, Naomi N. ;

Walewski, Jan .

LANCET, 2015, 385 (9980) :1853-1862

← 1 2 3 4 →